[1] Murphy CC, Lewis CL, Golin CE, et al. Underuse of surveillance colonoscopy in patients at increased risk of colorectal cancer. Am J Gastroenterol, 2015, 110: 633-641.
[2] Younossi ZM, Loomba R, Rinella ME, et al. Current and future therapeutic regimens for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Hepatology, 2017 [Epub ahead of Print].
[3] Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology, 2004, 40: 1387-1395.
[4] Lee JY, Kim KM, Lee SG, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol, 2007, 47: 239-244.
[5] Ding W, Fan J, Qin J. Association between nonalcoholic fatty liver disease and colorectal adenoma: a systematic review and meta-analysis. Int J Clin Exp Med, 2015, 8: 322-333.
[6] Shen H, Lipka S, Kumar A, et al. Association between nonalcoholic fatty liver disease and colorectal adenoma: a systemic review and meta-analysis. J Gastrointest Oncol,2014, 5: 440-446.
[7] Lee T, Yun KE, Chang Y, et al. Risk of colorectal neoplasia according to fatty liver severity and presence of gall bladder polyps. Dig Dis Sci, 2016, 61: 317-324.
[8] Wong VW, Wong GL, Tsang SW, et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut, 2011, 60: 829-836.
[9] Ahn JS, Sinn DH, Min YW, et al. Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. Aliment Pharmacol Ther, 2017, 45: 345-353.
[10] European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol, 2016, 64: 1388-1402. |
